[Federal Register Volume 62, Number 93 (Wednesday, May 14, 1997)]
[Notices]
[Pages 26516-26520]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-12607]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Program Announcement Number 801]
Cooperative Agreements to Conduct Research and Education Programs
on Lyme Disease in the United States
Introduction
The Centers for Disease Control and Prevention (CDC) announces the
expected availability of FY 1998 funds for a cooperative agreement
program to conduct research on Lyme disease and illnesses caused by
other related Borrelia species. Topics include: disease surveillance
and epidemiologic studies, ecologic studies, and the development,
implementation, and evaluation of prevention/control strategies. In
addition, funds are available for the development of educational
programs. This program's overall objective is to lower the incidence of
Lyme disease in hyperendemic states to 5 per 100,000 population or less
by the year 2000.
CDC is committed to achieving the health promotion and disease
prevention objectives of ``Healthy People 2000,'' a national activity
to reduce morbidity and mortality and improve the quality of life. This
announcement is related to the priority area of Immunization and
Infectious Diseases. (For ordering a copy of ``Healthy People 2000,''
see the Section ``Where to Obtain Additional Information.'')
Authority
This program is authorized under Sections 301 and 317(k)(2) of the
Public Health Service Act, as amended (42 U.S.C. 241 and 247b(k)(2)).
Smoke-Free Workplace
CDC encourages all grant recipients to provide a smoke-free
workplace and to promote the non-use of all tobacco products. Public
Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain
facilities that receive Federal funds in which education, library,
daycare, health care, and early childhood development services are
provided to children.
Eligible Applicants
Applications may be submitted by public and private nonprofit
organizations and governments and their agencies within the United
States. Thus, universities, colleges, research institutions, hospitals,
other public and private organizations, State and local health
departments, or their bona fide agents, federally recognized Indian
tribal governments, Indian tribes or Indian tribal organizations, and
small, minority and/or women-owned, nonprofit businesses are eligible
to apply as the principal investigating entities. These United States
entities may propose collaborative arrangements with investigators
outside the United States, provided the proposal has a direct impact on
United States public health.
Participation in proposed activities by scientists, health
professionals and educators with expertise and experience in Lyme
disease and its associated epidemiologic, environmental and
entomological aspects is desirable. In addition, combined program
activities involving State and local health departments, universities,
colleges, and private nonprofit organizations are encouraged.
Note: Effective January 1, 1996, Public Law 104-65 states that
an organization described in section 501(c)(4) of the Internal
Revenue Code of 1986 which engages in lobbying activities will not
be eligible for the receipt of Federal funds constituting an award,
grant, cooperative agreement, contract, loan, or any other form.
Availability of Funds
CDC projects approximately $1,700,000 of the President's budget
will be available for FY 1998 for cooperative agreements to conduct
research and education programs on Lyme disease in the United States.
However, this announcement is made prior to the actual appropriation of
fiscal year 1998 funds to allow new and competing continuation
applicants sufficient time to prepare applications, and to enable
timely award of the cooperative agreements. Approximately 10 to 15 new
and competing continuation awards will be made with a median award of
$150,000 ranging from $50,000 to $250,000. It is expected that the
awards will begin on or about February 15, 1998. Awards will be funded
for a 12-month budget period within a project period of up to three
years. Funding estimates may vary and are subject to change.
Continuation awards within the project period are made on the basis of
satisfactory progress and the availability of funds.
Applicants may apply for and receive support for activities under
one or more of the three activity areas (A.1., A.2., and/or A.3.)
listed in the Recipient Activities section. Approximately 35% of the
available funds will be allocated to develop improved disease
surveillance and conduct epidemiologic studies; approximately 40% of
the available funds will be allocated to conduct ecologic studies and
develop and implement strategies for prevention and control; and,
approximately 25% of the available funds will be allocated to educate
the public and health professionals on the primary and secondary
prevention of Lyme disease. Applications may be submitted for any or
all of the activities described above (any one or combination of the
three subjects areas). Each category will be scored separately.
Recipient Financial Participation
There are no matching or cost participation requirements; however,
the applicant's anticipated contribution to the overall program costs,
if any, should be provided on the application. These funds should not
supplant existing expenditures in this disease area.
Background
Lyme disease is one of the most important emerging infectious
diseases in the United States, accounting for more than 90% of all
reported vector-borne illness. The numbers of reported cases have
increased steadily, resulting in a thirty-fold rise between 1982 and
1996. More than 16,000 cases were reported by 44 States to the CDC in
1996.
Lyme borreliosis is a potentially serious and debilitating
infection that may lead to subacute and chronic disease of the joints,
the peripheral and central nervous system, the heart, and the skin.
Questions have been raised about microbial persistence and chronic Lyme
disease. Although transplacental transmission has been reported,
epidemiologic studies have not shown an association between Lyme
disease and adverse outcomes of pregnancy.
Lyme disease cases have been reported nationwide; however, the
disease is concentrated in three regions: the northeast and mid-
Atlantic, the north central, and the Pacific coastal regions.
Distribution of cases is principally related to the density of infected
tick vectors. Ixodes scapularis is the principal vector throughout the
northeastern, mid-Atlantic, and north central States, and is the cause
of
[[Page 26517]]
significant peridomestic transmission. Ixodes pacificus transmits the
disease in Pacific coastal areas. Ixodes spinipalpis maintains an
enzootic cycle in Colorado and California. The role of the putative
vectors in southern regions of the United States, Ixodes scapularis and
Amblyomma americanum, is not clear.
CDC has maintained a system of national surveillance for Lyme
disease since 1982. This system depends upon reporting of cases by
State health departments to CDC. It provides basic descriptive
epidemiologic information, defines trends in established endemic areas,
and monitors the emergence of the disease in new areas. The usefulness
of these surveillance data is limited by the application among States
of different surveillance methods--some active, some passive. In
addition, there is considerable lack of detection, under-reporting, and
misclassification of cases. The national surveillance system has not
provided reliable estimates of the total disease burden, but has given
a rough index for monitoring trends of incidences. The emergence of the
disease in new areas has been linked with geographic spread and
increased density of infected tick vectors, although the dynamics of
emergence are poorly understood.
There exists a great need to improve surveillance of human cases,
to identify and characterize the cycle of transmission among animal
reservoirs and arthropod vectors, to better define the geographic
distribution and ecologic determinants of these cycles throughout the
United States, and to quantify the risk of transmission to persons
under various circumstances of exposure. Epidemiologic and behavioral
studies are needed to better define risk factors for human infection so
that more effective strategies for prevention and control of disease
can be devised and implemented.
Research is needed on primary strategies involving community
participation in integrated pest management (suppression of tick
vectors, environmental modification, and vertebrate host management),
personal protection measures to reduce human contact with infected
ticks, the targeting, cost-benefits, and impact of anticipated
vaccines, and other specific prevention methods.
Education of the public and health care professionals is a
principal goal leading to primary prevention, and to secondary
prevention through early detection, diagnosis, and appropriate
treatment of infected persons. The effectiveness of education in
preventing infection under various circumstances of exposure, such as
periresidential, recreational, and occupational, needs to be evaluated
or adequately described in terms of health behavior.
Purpose
The purposes of these cooperative agreements are to: (1) Provide
assistance in determining the incidence and trends of Lyme disease in
various geographic regions of the United States, (2) measure the public
health impact of early and late stages of Lyme disease, (3) assess risk
factors associated with the transmission of the disease, including
behavioral and environmental factors, (4) determine the distribution
and density of vector tick species, determine B. burgdorferi infection
rates of these vectors, and characterize the ecologic factors which
result in high infection rates in tick and vertebrate host populations,
(5) develop, implement, and evaluate more effective prevention and
control strategies using a community intervention approach, and (6)
educate health professionals and the public on prevention through
personal protection and environmental interventions, and on the need
for early and accurate diagnosis, and appropriate treatment.
Program Requirements
In conducting activities to achieve the purpose of this program,
the recipient will be responsible for conducting selected activities
under A.1., A.2., and/or A.3. below, and CDC will be responsible for
conducting activities under B., below:
A. Recipient Activities
1. Disease Surveillance and Epidemiologic Studies (Conduct One or More
of the Following):
a. Implement, maintain, and evaluate an active Lyme disease
surveillance system based on the 1990 (or subsequent) national case
definition adopted by the Council of State and Territorial
Epidemiologists (CSTE). Determine the utility of laboratory-based
surveillance using standardized serologic tests for Lyme disease.
b. Conduct epidemiologic studies, utilizing descriptive,
correlative, analytical and seroepidemiologic methods to better
understand the epidemiology of the disease and to elucidate risk
factors for infection and disease in specific geographic foci.
c. Carry out studies to measure the public health burden of Lyme
disease and to determine the efficacy of various intervention
strategies for primary and secondary prevention.
d. Conduct studies to identify human populations at high risk of
infection and disease, including risks from periresidential,
occupational, and recreational exposures, and design studies to measure
the costs and benefits of various intervention strategies, including
behavior modification, integrated pest management, and vaccine use.
e. Conduct studies to identify and describe the emergence of Lyme
disease in previously nonendemic regions.
2. Conduct Ecologic Studies, Develop and Evaluate Prevention/Control
Strategies (Conduct One or More of the Following):
a. Initiate ecologic studies that will contribute information for
development of a nationwide map of Lyme disease risk based on ecologic,
entomologic, and epidemiologic data. Risk factors to be evaluated may
include distribution of vector ticks, density of vector ticks,
infection rate of vector ticks, efficiency of transmission of Lyme
disease spirochetes, reservoir competence of vertebrate hosts of B.
burgdorferi, density distribution of principal tick maintenance hosts,
and contact between infected ticks and humans.
b. Design, implement, and evaluate an Integrated Pest Management
(IPM) program that can be used to reduce Lyme disease in residential
and/or recreational settings. The proposed methods may include
community participation, acaricides in an area-wide or host-targeted
applications, alternative acaricides, habitat modification, host
management, or biological control. Emphasis should be placed on
adapting the use of an IPM program to communities or large scale
recreational areas.
c. Evaluate in tick and animal models whether commercial Lyme
disease vaccine preparations protect against various strains of B.
burgdorferi and closely related Borrelia species found in common
anthropophilic ticks in the United States. Develop anti-tick vaccines
that interrupt transmission of Ixodes scapularis-borne pathogens.
d. Culture and characterize the newly described spirochete B.
lonestari found in Amblyomma americanum ticks. Determine whether this
spirochete infects and causes disease in vertebrates, including humans.
3. Develop and Disseminate Prevention and Control Information on Lyme
Disease (Conduct One or More of the Following):
a. Provide information for health care providers and the public on
the distribution of Lyme disease in the geographic area being served by
the applicant. Update these data annually,
[[Page 26518]]
showing trends of incidence and other descriptive epidemiologic
characteristics of the disease in tabular and map formats.
b. Devise new and innovative methods for disseminating currently
developed educational materials to health care providers and the
general public on measures to prevent Lyme disease and on the early and
appropriate diagnosis and management of Lyme disease.
c. Develop informational materials for specific geographical areas
on the ecology, environmental and behavioral risk factors, and
prevention of Lyme disease.
d. Develop and publish information outlining practical methods to
reduce vector tick densities, based on research in residential areas of
high Lyme disease transmission.
e. Devise new and innovative methods to educate physicians, nurses,
physician assistants, and other front line health care providers about
Lyme disease, especially those that serve populations at high risk
because of periresidential, occupational or recreational exposures.
f. Devise new and innovative health communication methods to
increase awareness and knowledge of the general public about prevention
and control of Lyme disease.
B. CDC Activities
1. Provide technical assistance in the design and conduct of
research.
2. Assist in performing selected laboratory tests, as appropriate,
depending on the needs of the recipient.
3. Assist in the coordination of research activities among
different recipient sites.
4. Assist in the analysis of research data.
5. Assist in reviewing educational materials for medical and
scientific accuracy.
Technical Reporting Requirements
Semiannual progress reports are required and must be submitted no
later than 30 days after each semiannual reporting period. The
semiannual progress reports must include the following for each
program, function, or activity involved: (1) A comparison of actual
accomplishments to the goal established for the period; (2) the reasons
for failure, if established goals were not met; and (3) other pertinent
information including, when appropriate, analysis and explanation of
performance costs significantly higher than expected. The final
progress report is required no later than 90 days after the end of the
project period. All manuscripts published as a result of the work
supported in part or whole by the cooperative agreement will be
submitted with the progress reports.
An annual Financial Status Report (FSR) is required no later than
90 days after the end of each budget period.
An original and two copies of all reports should be submitted to
the Grants Management Branch, CDC.
Application Content
Applicants may apply for assistance for projects in one or more of
the subject areas as described in the Recipient Activities section. If
the applicant is applying under more than one subject area, a separate
narrative, budget, and budget justification must be submitted for each
subject area. Each application should consist of the following:
1. The abstract should summarize the background, needs, goals,
objective and methods of the proposal on one page.
2. The program narrative should include the following sections:
background, objectives, methods, plan of operation, and plan of
evaluation. List and briefly describe specific, measurable, realistic,
and time-phased objectives.
3. A budget justification is required for all budget items and must
be submitted with Standard Form 424A, ``Budget Information,'' as part
of PHS 5161-1 (Revised 7/92). The budget should include the total funds
requested for the project, with separate budgets and justifications for
each recipient activity/component, i.e., surveillance and
epidemiological studies; ecologic studies and prevention and control
activities; and education (development and dissemination of disease
information). For applicants requesting funding for subcontracts,
include the name of the person or organization to receive the
subcontract, the method of selection, the period of performance, and a
description of the subcontracted service requested.
4. If the proposed project involves human subjects, whether or not
exempt from Department of Health and Human Services (DHHS) regulations,
describe in the narrative adequate procedures for the protection of
human subjects.
5. Also, ensure that women, racial and ethnic minority populations
are appropriately represented in applications for research involving
human subjects by including a description of the composition of the
proposed study population (for example, addressing the inclusion of
women and members of minority groups and their sub-populations in the
section that will describe the research design). The applicant will
provide an explanation when the investigator cannot control the race,
ethnicity and/or sex of the subjects. See Other Requirements for
additional information.
When applicable, letters of support must be included in an appendix
if applicants anticipate the participation of other organizations or
political subdivisions in conducting proposed activities. Specific
roles and responsibilities must be delineated.
Notice of Intent To Apply
In order to assist CDC in planning for and executing the evaluation
of applications submitted under this Program Announcement, all parties
intending to submit an application are requested to inform CDC of their
intention to do so no later than June 13, 1997. Notification should
include: (1) Name and address of institution, (2) name, address and
telephone number of contact person, and (3) which recipient
activity(ies) application will be submitted under. Notification may be
provided by facsimile or postal mail to Sharron P. Orum, Grants
Management Officer, Grants Management Branch, Centers for Disease
Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Room 305,
Mailstop E-18, Atlanta, GA 30305, facsimile (404) 842-6513.
Required Format for Applications
Due to the need to reproduce copies of the applications for the
reviewers, ALL pages of the application MUST be in the following
format.
1. The original and two copies must be UNSTAPLED and UNBOUND.
2. ALL pages must be clearly numbered, and a complete index to the
application and its appendices must be included.
3. Begin each separate section on a new page.
4. All materials must be typewritten, single-spaced, using a font
no smaller than a size 10, and typed ONLY on 8\1/2\'' by 11'' paper.
5. Any reprints, brochures, or other enclosures must be copied onto
8\1/2\'' by 11'' paper by the applicant.
6. All pages must be printed on ONE side only, with at least 1''
margins, headers, and footers.
7. The application narrative for each recipient activity subject
area (of the three subject areas) must be limited to 10 pages,
excluding abstract, budget, and appendices.
8. Materials that are part of the basic plan must not be placed in
the appendices.
9. If the applicant is applying for assistance for more than one of
the three
[[Page 26519]]
focus areas/components, a separate narrative and budget must be
submitted for each focus area/component.
Evaluation Criteria
Evaluation Criteria for Proposals for Activity A.1., Disease
Surveillance and Epidemiological Studies; Activity A.2., Ecologic
Studies and Prevention/Control Strategies
Applications will be reviewed and evaluated according to the
following criteria: (Total 100 points).
1. The applicant's understanding of the purpose of the proposed
activity and the feasibility of accomplishing the outcomes desired. (5
points)
2. The extent to which background information and other data
demonstrate that the applicant has the appropriate organizational
structure, administrative support, and technical expertise to conduct
the work proposed and has access to stated target populations or other
study objects. (10 points)
3. The degree to which the proposed objectives are consistent with
the purpose as defined in the ``Purpose'' section of this application
and are specific, measurable, and time-phased. (5 points)
4. The degree to which the research plans will enable the applicant
to achieve the stated objectives. The plans should specify the who,
what, where, how, and timing for the start and completion of each
activity. (25 points)
5. The quality of the research methods and instruments to be used.
(If the proposal involves human subjects, the degree to which the
applicant has met CDC Policy requirements regarding the inclusion of
women, ethnic, and racial groups in the proposed research will be
evaluated. This includes: (1) The proposed plan for the inclusion of
both sexes and racial and ethnic minority populations for appropriate
representation; (2) the proposed justification when representation is
limited or absent; (3) a statement as to whether the design of the
study is adequate to measure differences when warranted; and (4) a
statement as to whether the plans for recruitment and outreach for
study participants include the process of establishing partnerships
with community(ies) and recognition of mutual benefits.) (25 points)
6. The quality of the proposed methods for evaluating the project.
(5 points)
7. The extent to which qualifications (including expertise and
experience in relevant work) of project personnel, and the projected
level of effort by each toward accomplishment of the proposed
activities demonstrate the ability to successfully conduct the proposed
work. (10 points)
8. The degree to which the proposal addresses one or more of the
priority funding areas:
a. Surveillance and epidemiological studies that target geographic
areas of high endemicity/enzooticity and human populations at high
risk, and populations in circumstances of emerging risk (5 points);
b. The development, implementation, and evaluation of community-
based strategies of primary prevention and control, including methods
for vector suppression and personal protection (5 points);
c. Studies that measure the public health impact of Lyme disease,
or that estimate the costs and benefits of various strategies of
prevention and control, including vaccination (5 points).
9. The extent to which the budget is reasonable, clearly justified,
and consistent with the intended use of cooperative agreement funds.
(not scored)
Evaluation Criteria for Proposals for Activity A.3., Development and
Dissemination of Disease Information/Education
Applications will be reviewed and evaluated according to the
following criteria: (Total 100 points)
1. The applicant's understanding of the purpose of the proposed
educational intervention/activity and the feasibility of accomplishing
the outcomes desired. (10 points)
2. The extent to which background information and other data
demonstrate that the applicant has the appropriate organizational
structure, administrative support, and technical expertise to research,
design, develop, and disseminate the proposed educational materials,
and to access appropriate target populations. (15 points)
3. The degree to which the proposed objectives are consistent with
the defined purpose as defined in the ``Purpose'' section of this
application and are specific, measurable, and time-phased. (10 points)
4. The degree to which the educational research, design,
development, and dissemination plans demonstrate the ability of the
applicant to achieve the stated objectives. The plan will specify the
who, what, where, how, and timing for the start and completion of each
activity. (20 points)
5. The quality of the educational research, design, development,
and dissemination methods and instruments to be used. (If the proposal
involves human subjects, the following will be evaluated: the degree to
which the applicant has met CDC Policy requirements regarding the
inclusion of women, ethnic, and racial groups in the proposed research.
This includes: (1) The proposed plan for the inclusion of both sexes
and racial and ethnic minority populations for appropriate
representation; (2) the proposed justification when representation is
limited or absent; (3) a statement as to whether the design of the
study is adequate to measure differences when warranted; and (4) a
statement as to whether the plans for recruitment and outreach for
study participants include the process of establishing partnerships
with community(ies) and recognition of mutual benefits. (20 points)
6. The soundness of the proposed methods for measuring changes in
behavior and prevention effectiveness of the educational activity/
intervention, including the pre-and post-testing of a representative
sample of the intended target population. (15 points)
7. The extent to which qualifications (including training and
experience in work with Lyme disease) of project personnel, and the
projected level of effort by each toward accomplishment of the proposed
activities are described. (10 points)
8. The extent to which the budget is reasonable, clearly justified,
and consistent with the intended use of cooperative agreement funds.
(not scored)
Funding Priorities
Priority will be given to applications in the areas of surveillance
and epidemiologic studies that target geographic areas of high
endemicity/enzooticity and human populations at high risk; to
applications that relate to studies of community-based strategies of
primary prevention and control, including methods for vector
suppression and personal protection; and to applications which focus on
education of health care providers and on the evaluation of education
effectiveness.
Interested persons are invited to comment on the proposed funding
priorities. All comments received on or before June 26, 1997, will be
considered before the final funding priorities are established. If any
funding priority should change as a result of any comments received, a
revised Announcement will be published in the Federal Register and
revised applications will be accepted prior to the final receipt of
applications.
Written comments should be addressed to: Sharron Orum, Grants
Management Officer, Grants
[[Page 26520]]
Management Branch, Procurement and Grants Office, Centers for Disease
Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Room 305,
Mailstop E-18, Atlanta, GA 30305. All comments should reference the
Program Announcement Number 801.
Executive Order 12372 Review
This program is not subject to the Executive Order 12372 review.
Public Health System Reporting Requirements
This program is not subject to the Public Health System Reporting
Requirements.
Catalog of Federal Domestic Assistance Number
The Catalog of Federal Domestic Assistance Number is 93.942.
Other Requirements
Paperwork Reduction Act
Projects that involve collection of information from 10 or more
individuals and funded by cooperative agreements will be subject to
review and approval by the Office of Management and Budget (OMB) under
the Paperwork Reduction Act.
Human Subjects
If the proposed project involves research on human subjects, the
applicant must comply with the Department of Health and Human Services
Regulations (45 CFR Part 46) regarding the protection of human
subjects. Assurance must be provided which demonstrates that the
project will be subject to initial and continuing review by an
appropriate institutional review committee. In addition to other
applicable committees, Indian Health Service (IHS) institutional review
committees also must review the project if any component of IHS will be
involved or will support the research. If any American Indian community
is involved, its Tribal government must also approve that portion of
the project applicable to it. The applicant will be responsible for
providing evidence of this assurance in accordance with the appropriate
guidelines and forms provided in the application kit.
Animal Subjects
If the proposed project involves research on animal subjects, the
applicant must comply with the ``PHS Policy on Humane Care and Use of
Laboratory Animals to Awardee Institutions.'' An applicant organization
proposing to use vertebrate animals in CDC-supported activities must
file an Animal Welfare Assurance with the Office for the Protection
from Research Risks at the National Institutes of Health.
Women, Racial and Ethnic Minorities
It is the policy of the Centers for Disease Control and Prevention
(CDC) and the Agency for Toxic Substances and Disease Registry (ATSDR)
to ensure that individuals of both sexes and the various racial and
ethnic groups will be included in CDC/ATSDR-supported research projects
involving human subjects, whenever feasible and appropriate. Racial and
ethnic groups are those defined in OMB Directive No. 15 and include
American Indian, Alaskan Native, Asian, Pacific Islander, Black and
Hispanic. Applicants will ensure that women, racial and ethnic minority
populations are appropriately represented in applications for research
involving human subjects. Where clear and compelling rationale exist
that inclusion is inappropriate or not feasible, this situation must be
explained as part of the application. This policy does not apply to
research studies when the investigator cannot control the race,
ethnicity and/or sex of subjects. Further guidance to this policy is
contained in the Federal Register, Vol. 60, No. 179, pages 47947-47951,
dated Friday, September 15, 1995.
Application Submission and Deadline
The original and two copies of the application form PHS 5161-1
(Revised 7-92, OMB number 0937-0189) must be submitted to Sharron Orum,
Grants Management Officer, Grants Management Branch, Procurement and
Grants Office, Centers for Disease Control and Prevention (CDC), 255
East Paces Ferry Road, NE., Room 305, Mailstop E-18, Atlanta, GA 30305,
on or before August 1, 1997.
1. Deadline: Applications will be considered as meeting the
deadline if they are either:
a. Received on or before the deadline date; or
b. Sent on or before the deadline date and received in time for
submission to the objective review group. (Applicants must request a
legibly dated U.S. Postal Service postmark or obtain a legibly dated
receipt from a commercial carrier or the U.S. Postal Service. Private
metered postmarks will not be acceptable as proof of timely mailing).
2. Late Applications: Applications which do not meet the criteria
in 1.a. or 1.b. above are considered late applications. Late
applications will not be considered and will be returned to the
applicant.
Where To Obtain Additional Information
To receive additional written information, call (404) 332-4561. You
will be asked to leave your name, address, and telephone number. Please
refer to Announcement #801. You will receive a complete program
description, information on application procedures and application
forms. If you have questions after reviewing the contents of all the
documents, business management technical assistance may be obtained
from Gladys T. Gissentanna, Grants Management Specialist, Grants
Management Branch, Procurement and Grants Office, Centers for Disease
Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Room 314,
Mailstop E-18, Atlanta, GA 30305, telephone (404) 842-6801.
Programmatic technical assistance may be obtained from David Dennis,
M.D. or Duane Gubler, Sc.D., Division of Vector-Borne Infectious
Diseases, National Center for Infectious Diseases, Centers for Disease
Control and Prevention (CDC), Fort Collins, CO 80522, telephone (970)
221-6400. You may also obtain this announcement from one of two
Internet sites on the actual publication date: CDC's homepage at http:/
/www.cdc.gov or the Government Printing Office homepage (including free
on-line access to the Federal Register at http://www.access.gpo.gov).
Other CDC Announcements are also listed on the Internet on the CDC
homepage.
Please refer to Announcement Number 801 when requesting information
and submitting an application.
Potential applicants may obtain a copy of ``Healthy People 2000''
(Full Report, Stock No. 017-001-00474-0) or ``Healthy People 2000''
(Summary Report, Stock No. 017-001-00473-1) referenced in the
``Introduction'' through the Superintendent of Documents, Government
Printing Office, Washington, D.C. 20402-9325, telephone (202) 512-1800.
Dated: May 8, 1997.
Joseph R. Carter,
Acting Associate Director for Management and Operations, Centers for
Disease Control and Prevention (CDC).
[FR Doc. 97-12607 Filed 5-13-97; 8:45 am]
BILLING CODE 4163-18-P
